Biomea Fusion (NASDAQ: BMEA)

Last close As at 21/02/2025

USD3.65

0.08 (2.24%)

Market capitalisation

USD130m

Biomea Fusion is a US-based clinical-stage biopharmaceutical company focused on the development of novel covalent small molecules for the treatment of metabolic diseases and genetically defined cancers.

Latest Insights

Healthcare | Non client QV

Biomea Fusion — An innovative approach to diabetes and obesity

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Analyst, Healthcare

Key Management

  • Franco Valle

    CFO

  • Thomas Butler

    Founder, chairman and CEO

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free